Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists
Executive Summary
Cephalon's acquisition of US rights to Alkermes' Vivitrex, a long-acting formulation of the alcohol abuse drug naltrexone, is a clear sign that mid-sized companies with marketed products can--thanks to their significant cash flows--contend with Big Pharma for important specialist products.
You may also be interested in...
Reformulation has Ruled in Neurology Dealmaking--Until Now
The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.
The Rise of Regional Dealmaking
Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.
The Rise of Regional Dealmaking
Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.